Cargando…

Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy

AIMS: Inflammation indexes had been associated with overall survival (OS) and immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). MATERIALS & METHODS: in 72 patients treated with ICIs for metastatic urothelial carcinoma (mUC) we evaluate difference...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dionese, Michele, Basso, Umberto, Pierantoni, Francesco, Lai, Eleonora, Cavasin, Nicolò, Erbetta, Elisa, Jubran, Salim, Bonomi, Giorgio, Bimbatti, Davide, Maruzzo, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Science Ltd 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357407/ https://www.ncbi.nlm.nih.gov/pubmed/37485441 http://dx.doi.org/10.2144/fsoa-2023-0049

Ejemplares similares

Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: A real-world, single-centre experience
por: Bimbatti, Davide, et al.
Publicado: (2022)

Advanced Non-Clear Cell Renal Cell Carcinoma Treatments and Survival: A Real-World Single-Centre Experience
por: Bimbatti, Davide, et al.
Publicado: (2023)

Tumour Seeding After a Thoracic Biopsy for Renal Cell Carcinoma: A Case Report and a Review of the Literature
por: Michele, Dionese, et al.
Publicado: (2021)

Patient Reported Outcomes, Paternity, Relationship, and Fertility in Testicular Cancer Survivors: Results from a Prospective Observational Single Institution Trial
por: Bimbatti, Davide, et al.
Publicado: (2022)

Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)
por: Maruzzo, Marco, et al.
Publicado: (2021)

Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
por: Maruzzo, Marco, et al.
Publicado: (2022)

Prognostic Stratification of Metastatic Prostate Cancer Patients Treated With Abiraterone and Enzalutamide Through an Integrated Analysis of Circulating Free microRNAs and Clinical Parameters
por: Sharova, Evgeniya, et al.
Publicado: (2021)

Impressive reduction of brain metastasis radionecrosis after cabozantinib therapy in metastatic renal carcinoma: A case report and review of the literature
por: Lolli, Jacopo, et al.
Publicado: (2023)

Corrigendum: Impressive reduction of brain metastasis radionecrosis after cabozantinib therapy in metastatic renal carcinoma: a case report and review of the literature
por: Lolli, Jacopo, et al.
Publicado: (2023)

Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline
por: Maruzzo, Marco, et al.
Publicado: (2016)

Trabectedin Drug Holiday and Rechallenge in Soft Tissue Sarcomas: Report of 4 Cases and Literature Review
por: Pierantoni, Francesco, et al.
Publicado: (2019)

Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma
por: Shao, Zhiying, et al.
Publicado: (2016)

Renal cell carcinoma: the population, real world, and cost-of-illness
por: Buja, Alessandra, et al.
Publicado: (2022)

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
por: Lolli, Cristian, et al.
Publicado: (2016)

Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators
por: Stellato, Marco, et al.
Publicado: (2021)

The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma
por: Ozaki, Kai, et al.
Publicado: (2021)

Development of a Prognostic AI-Monitor for Metastatic Urothelial Cancer Patients Receiving Immunotherapy
por: Trebeschi, Stefano, et al.
Publicado: (2021)

Homologous Recombination Related Signatures Predict Prognosis and Immunotherapy Response in Metastatic Urothelial Carcinoma
por: Li, Pan, et al.
Publicado: (2022)

A CASE OF RAPIDLY PROGRESSIVE RETINOPATHY ASSOCIATED WITH PEMBROLIZUMAB IMMUNOTHERAPY FOR METASTATIC UROTHELIAL CARCINOMA
por: Sakai, Daiki, et al.
Publicado: (2023)

Metastatic urothelial carcinoma()()
por: Gómez-Moyano, Elisabeth, et al.
Publicado: (2021)

Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases
por: Zanardi, Elisa, et al.
Publicado: (2014)

Impact of Prognostic Nutritional Index on Overall Survival for Patients with Metastatic Urothelial Carcinoma
por: Hsieh, Meng-Che, et al.
Publicado: (2018)

Cerebral metastasis during remission after immunotherapy for metastatic urothelial carcinoma: A case report
por: Iwata, Shohei, et al.
Publicado: (2021)

Complement and coagulation cascades pathway-related signature as a predictor of immunotherapy in metastatic urothelial cancer
por: Gong, Zheng, et al.
Publicado: (2023)

Prognostic Value of Plasma and Urine Glycosaminoglycan Scores in Clear Cell Renal Cell Carcinoma
por: Gatto, Francesco, et al.
Publicado: (2016)

Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review
por: Kim, Tae Jin, et al.
Publicado: (2020)

Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment
por: Sternberg, Cora N., et al.
Publicado: (2022)

Immunotherapy with or without targeted therapy for metastatic upper tract urothelial carcinoma: case report and literature review
por: Ni, Kangxin, et al.
Publicado: (2023)

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
por: Klümper, Niklas, et al.
Publicado: (2023)

Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives
por: Zichi, Clizia, et al.
Publicado: (2017)

Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives
por: Kitamura, Hiroshi, et al.
Publicado: (2011)

Immunotherapy in urothelial carcinoma: fade or future standard?
por: Breyer, Johannes, et al.
Publicado: (2016)

Update on the Treatment of Metastatic Urothelial Carcinoma
por: Bukhari, Nedal, et al.
Publicado: (2018)

Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma
por: Hui, Gavin, et al.
Publicado: (2023)

Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
por: Tassinari, Elisa, et al.
Publicado: (2022)

Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa)
por: Bergamo, Francesca, et al.
Publicado: (2014)

Cost of illness of urothelial bladder cancer in Italy
por: Gerace, Claudio, et al.
Publicado: (2017)

Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma
por: Ning, Yang‐Min, et al.
Publicado: (2017)

Immune escape mechanisms and immunotherapy of urothelial bladder cancer
por: Yang, Zhao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t4aeafubbli11jlsra2b3s05pk